GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Online Resource
    Online Resource
    Springer Science and Business Media LLC ; 2016
    In:  Canadian Journal of Anesthesia/Journal canadien d'anesthésie Vol. 63, No. 9 ( 2016-9), p. 1110-1111
    In: Canadian Journal of Anesthesia/Journal canadien d'anesthésie, Springer Science and Business Media LLC, Vol. 63, No. 9 ( 2016-9), p. 1110-1111
    Type of Medium: Online Resource
    ISSN: 0832-610X , 1496-8975
    Language: English
    Publisher: Springer Science and Business Media LLC
    Publication Date: 2016
    detail.hit.zdb_id: 2050416-0
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    In: Cureus, Springer Science and Business Media LLC
    Type of Medium: Online Resource
    ISSN: 2168-8184
    Language: English
    Publisher: Springer Science and Business Media LLC
    Publication Date: 2015
    detail.hit.zdb_id: 2747273-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    In: Cureus, Springer Science and Business Media LLC
    Type of Medium: Online Resource
    ISSN: 2168-8184
    Language: English
    Publisher: Springer Science and Business Media LLC
    Publication Date: 2018
    detail.hit.zdb_id: 2747273-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    Online Resource
    Online Resource
    American Society of Hematology ; 2012
    In:  Blood Vol. 120, No. 21 ( 2012-11-16), p. 3432-3432
    In: Blood, American Society of Hematology, Vol. 120, No. 21 ( 2012-11-16), p. 3432-3432
    Abstract: Abstract 3432 Patients who undergo on-pump coronary artery bypass graft surgery (CABG) are at an increased risk of bleeding due physiologic, mechanical and pharmacologic disruption of hemostasis. The use of topically applied antifibrinolytic agents has been explored as a blood-conservation adjunct to reduce post-operative bleeding in cardiac surgery. Analysis of pooled results in a meta-analysis published by Abrishami et al. in 2009 showed that a significant reduction in blood loss could be achieved utilizing topical tranexamic acid in the absence of concurrent intravenous antifibrinolytic agents. However, current blood conservation clinical practice guidelines recommend the use of intravenous lysine analogues to limit peri-operative blood loss. Presently, there is no published prospective data evaluating blood loss in CABG patients who have received intravenous tranexamic acid, plus topical tranexamic acid versus placebo. Our study was designed to determine whether combined intravenous and topical application of tranexamic acid would reduce post-CABG blood loss in low-risk bypass surgery candidates. A sample calculation based on pilot study data analysis concluded that a minimum total of 74 patients was required, allowing 80% power to detect a 200mL difference in total blood loss (Type I error = 0.05) between groups. In our prospective, double-blind, randomized controlled trial, patients enrolled were randomly assigned to receive an intra-operative cardiac bath of either normal saline or tranexamic acid solution prior to sternotomy closure. All participants received intravenous tranexamic acid prior to the initiation of circulatory bypass. Research subject participation ended upon transfer out of the intensive care unit. Primary outcomes included the total volume of chest tube blood loss and number of transfusions administered following CABG. Secondary outcomes included chest tube loss volumes at 6 hours and 12 hours. Between December 1, 2011 and April 30, 2012, a total of 41 patients who underwent randomization were included in final data analysis. Baseline characteristics of patients enrolled in both groups were similar. Post-CABG losses at chest tube removal were found to be significantly reduced in the patients who received topical tranexamic acid. Mean chest tube loss in the placebo group (n=18) was 789mL versus 632mL in the topical tranexamic acid group (n=23), with a difference of 157mL (Figure 1, p value of student t-test 0.0493). A significantly greater proportion of patients in the placebo group were found to bleed more than 700mL at chest tube removal, in comparison with the topical tranexamic acid group (72.2% versus 30.4%, p value of chi-squared test 0.0079). Chest tubes remained in situ for a mean duration of 20 hours and 19 hours, respectively. None of the patients received post-operative red cell transfusions. One patient, randomized to the topical tranexamic acid group, received a single dose each of platelets and cryoprecipitate post-operatively. The application of topical tranexamic acid did not significantly reduce blood loss at 6 hours and 12 hours, with a difference of 76mL (p=0.1876) and 106mL (p=0.0930) respectively. The application of topical tranexamic acid reduces post-operative blood loss in patients undergoing on-pump CABG who have received intravenous tranexamic acid. There was no difference in blood product use between groups. Further studies must be carried out to investigate long-term outcomes of this practice and its applicability in high-risk cardiac surgery patients. (ClinicalTrials.gov number, NCT01519245.) Disclosures: Off Label Use: Intravenous and topical application of tranexamic acid in cardiac surgery.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2012
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 5
    Online Resource
    Online Resource
    American Society of Hematology ; 2018
    In:  Blood Vol. 132, No. Supplement 1 ( 2018-11-29), p. 5074-5074
    In: Blood, American Society of Hematology, Vol. 132, No. Supplement 1 ( 2018-11-29), p. 5074-5074
    Abstract: Plasma is a blood component frequently used in inappropriate clinical contexts. A 2013 frozen plasma utilization audit in Ontario found that 52% of orders for plasma were inappropriate, while plasma requested for appropriate indications was frequently under-dosed (less than 10 mL/kg administered). Local trends of plasma utilization have not previously been audited. We hypothesized that hospital sites within the former Saskatoon Health Region would have similar rates of inappropriate plasma transfusion and under-dosing as reported by other recent Canadian audits. This retrospective, quality improvement audit was completed evaluating transfused units of fresh frozen plasma and frozen plasma (collectively known as plasma), given between January and September 2017 at the two largest tertiary care hospitals in Saskatoon, Saskatchewan - Royal University Hospital (RUH) and St. Paul's Hospital (SPH). Data collected included: patient demographics, indication for plasma transfusion, plasma dose, coagulation parameters pre- and post-transfusion, specialty of ordering physician, location of transfusion, and concurrent vitamin K use. Appropriateness of plasma utilization was judged according to the Ontario Clinical Practice Recommendations for the Use of Frozen Plasma. Appropriate indications for plasma transfusion included: massive hemorrhage, intraoperative coagulopathy during cardiac surgery, and patients with active bleeding or need for invasive procedures with laboratory evidence of coagulopathy (INR [International Normalized Ratio] ≥ 1.5). Inappropriate indications for plasma transfusion included: correction of laboratory evidence of coagulopathy in the absence of bleeding or need for invasive procedures, reversal of warfarin when Prothrombin Complex Concentrate (PCC) was available, reversal of other anticoagulants, and an INR of 1.5 or less or for whom the INR was unknown. Plasma transfusion to patients with INR of 1.5 or less or with an unknown INR was not considered inappropriate in cases of massive hemorrhage. According to the predefined criteria, each plasma transfusion during our study period was individually reviewed and classified as appropriate or inappropriate. A total of 270 adult and pediatric patients received plasma transfusion during our study period. Patients receiving plasma for therapeutic plasma exchange were excluded. Final analysis included 244 patients, representing 392 transfusion events and 891 units of plasma. Among adult patients at RUH and SPH, 50.5% of plasma transfusions were judged to be inappropriate. The most common inappropriate indication in adult patients (26.5%) was plasma transfusion to patients with an INR of 1.5 or less, or for whom INR was not measured (6.3%). Despite availability of PCC, 5% of plasma orders for adults were for the reversal of warfarin. The average plasma dose ordered for adults was 2 units per transfusion event, which is unlikely to be an appropriate dose for an average sized adult. In adult patients, transfusion of plasma was requested primarily by: critical care physicians (28.6%), cardiac surgeons (16.0%), and general internists (15.3%). Among pediatric patients at RUH, 79.8% of plasma transfusions were judged to be inappropriate, with the most common inappropriate request in pediatric patients (38.5%) cited as hemodynamic support without coagulopathy or massive hemorrhage. Our study demonstrated that the rate of inappropriate plasma transfusion at two major Saskatoon urban hospital sites was similar to that recently published in Ontario. It is reassuring that plasma transfusion for warfarin reversal was found to be only 5%, suggesting broad awareness of PCC availability. Plasma transfused to adults was found to frequently be under-dosed, suggesting patients are being exposed to the potential risks of plasma transfusion with limited clinical benefit. These results highlight plasma transfusion utilization and appropriateness as an area of educational need among both adult and pediatric clinicians. Implementation of strategies including local clinical practice guidelines for plasma transfusion, plasma order screening by the transfusion medicine laboratory, or a plasma transfusion order set may optimize plasma utilization and enhance patient safety by reducing unnecessary patient exposure to plasma transfusion. Disclosures No relevant conflicts of interest to declare.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2018
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 6
    Online Resource
    Online Resource
    American Society of Hematology ; 2016
    In:  Blood Vol. 128, No. 22 ( 2016-12-02), p. 3402-3402
    In: Blood, American Society of Hematology, Vol. 128, No. 22 ( 2016-12-02), p. 3402-3402
    Abstract: Introduction: Donor selection for allogeneic hematopoietic stem cell transplant (allo-HSCT) is dependent on matching with the intended recipient HLA allele profile, but not blood group compatibility. Red blood cell (RBC) phenotype matching is not considered, even if recipient alloantibodies are present pre-HSCT. Historically, up to 3.7% of allo-HSCT recipients have been found to develop new RBC alloantibodies following allo-HSCT. We completed an audit of all adult and pediatric allo-HSCT recipients of the Alberta Bone Marrow and Blood Cell Transplant Program to define the rate of RBC alloimmunization, and evaluate the impact of this RBC alloantibody presence on donor marrow engraftment in our allo-HSCT recipient population. Methods:A retrospective review was completed including all allogeneic pediatric and adult HSCT recipients between January 1, 2007 and January 1, 2015. Data was obtained from review of cellular therapy laboratory electronic records with red cell alloantibody information extracted manually from the transfusion medicine laboratory information system. Results: A total of 674 patients, including 104 pediatric recipients ( 〈 18 years old), underwent 697 allo-HSCT procedures (591 peripheral blood, 45 marrow, 61 cord blood). The mean HSCT recipient age was 40 (range 0-66) and most common HSCT indication was acute myeloid leukemia. Myeloablative conditioning was given to all adults and 86% of pediatric recipients. Fully HLA matched grafts were provided to 77% of recipients. ABO compatibility status of allo-HSCT procedures included the following: 362 (52%) ABO identical grafts, 154 (22%) grafts with a minor incompatibility, 143 (21%) grafts with a major incompatibility, and 38 (5.0%) grafts with bidirectional incompatibility. Rh mismatches were present in 165 (24%) of donor-recipient pairs. A total of 47 allo-HSCT recipients, including 3 pediatric and 44 adult patients, were found to have RBC alloantibodies before or after allo-HSCT. A total of 45 (6.4%) of allo-HSCT recipients had detectable RBC alloantibodies pre-HSCT, with 69 individual alloantibodies identified. The most common RBC alloantibody was anti-E (30%). Antibody screen results available on the day of or following HSCT in 43 allo-HSCT recipients found: 12 (28%) with antibody disappearance pre-HSCT and a negative screen on the date of allo-HSCT, 15 (35%) with antibody waning to disappearance after allo-HSCT, and 11 (26%) with persistence of pre-HSCT antibodies following allo-HSCT. New post-HSCT RBC alloantibodies were detected in 3 adult recipients of peripheral blood collected stem cell grafts (anti-D; anti-Kpa; anti-K plus anti-E), with an overall rate of 0.4%. These patients all received myeloablative conditioning and grafts which were ABO identical or had a minor ABO incompatibility. The anti-D antibody developed post-transplant in an Rh positive recipient of an Rh negative graft. Thus, the calculated overall rate of anti-D development in Rh mismatched HSCT recipients was 0.6%. There was no observed impact on neutrophil and platelet engraftment comparing adult allo-HSCT recipients who did and did not have pre-HSCT RBC alloantibodies. Conclusion: The risk of post-HSCT RBC alloantibody development is very low, even in Rh mismatched donor-recipient pairs. ABO incompatibility does not affect the risk of post-HSCT alloantibody development. Allo-HSCT recipients infrequently have pre-HSCT RBC alloantibodies, which may disappear after myeloablative conditioning. The presence of RBC alloantibodies pre-HSCT does not appear to impact donor marrow engraftment. The results of our retrospective study are limited by the availability, timing and frequency of post-HSCT antibody screen investigations. The decision to perform an antibody screen post-HSCT is a clinical one, typically dependent on recipient transfusion needs. Further prospective research is required to more accurately determine the rate of new post-HSCT alloantibody development and duration of alloantibody persistence or disappearance in allo-HSCT recipients. Results of these studies may also help guide RBC transfusion decisions in HSCT recipients known to have pre-HSCT RBC alloantibodies with proven engraftment and a negative post-HSCT antibody screen. Disclosures No relevant conflicts of interest to declare.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2016
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 7
    Online Resource
    Online Resource
    American Society of Hematology ; 2016
    In:  Blood Vol. 128, No. 22 ( 2016-12-02), p. 3394-3394
    In: Blood, American Society of Hematology, Vol. 128, No. 22 ( 2016-12-02), p. 3394-3394
    Abstract: Introduction: The selection of an allogeneic hematopoietic stem cell transplant (allo-HSCT) donor is highly dependent on human leukocyte antigen (HLA) allele profile matching with that of the intended recipient to minimize graft-related complications and improve post-transplant outcomes. Although ABO compatibility simplifies recipient transfusion needs, transplantation of an ABO incompatible graft has been identified not to have a significant impact on marrow engraftment or recipient survival. We completed an audit of adult allo-HSCT recipients of the Alberta Bone Marrow and Blood Cell Transplant Program to evaluate the impact of ABO incompatibility on engraftment in our allo-HSCT recipient population. Methods: A retrospective review including all adult allo-HSCT recipients between January 1, 2008 and January 1, 2015 was performed. Data was obtained from review of cellular therapy laboratory electronic records, with blood group confirmation by the transfusion medicine laboratory information system. Statistical calculations were completed using the unpaired t test. Results:A total of 513 adult patients underwent 528 allo-HSCT procedures (493 peripheral blood, 12 marrow, 23 cord blood). The mean HSCT recipient age was 46 (range 17-66) with 291 (57%) male recipients. The most common HSCT indication was acute myeloid leukemia. All allo-HSCT recipients received myeloablative conditioning. A total of 91% of recipients were conditioned with a regimen of Fludarabine-Busulfan-ATG, with or without total body irradiation. ABO compatibility status for allo-HSCT procedures included the following: 264 (50%) ABO identical grafts, 125 (24%) grafts with a minor incompatibility, 113 (21%) grafts with a major incompatibility, and 26 (5%) grafts with bidirectional incompatibility. HLA matching data was available for 447 allo-HSCT procedures. A total of 350 (78%) patients were recipients of fully HLA matched grafts (340 peripheral blood, 9 marrow, 1 cord blood). Taking into consideration ABO compatibility status, 10/10 HLA matched peripheral blood or marrow grafts were provided to 89% of ABO identical graft recipients, 77% of recipients each with a minor or major incompatibility, and 65% of recipients with a bidirectional incompatibility. Cellular engraftment including the number of days until absolute neutrophil count (ANC) 〉 1.0 x 106/L and platelet count 〉 20 x 109/L was available for 496 (94%) of all transplant procedures. A total of 34 transplant recipients did not successfully engraft one or both cell lines. A summary of recipient engraftment data for each category of ABO matching according to stem cell source appears in Table 1. Conclusion:In our study population, the risk of non-engraftment is lowest in recipients of ABO identical peripheral blood or marrow source donor stem cells. Time to cellular engraftment following allo-HSCT transplant with peripheral blood or marrow source stem cells of minor or major ABO incompatibility is similar to that of an ABO identical donor, while platelet engraftment appears to be prolonged in the setting of a bidirectional incompatibility. However, the small number of recipients of grafts with a bidirectional incompatibility and the large standard deviation affects our confidence in this result. The impact of ABO matching on engraftment appears to be the greatest in cord blood transplants. The risk of cellular non-engraftment is variable among all ABO compatibility categories, though the time to platelet engraftment is significantly prolonged in recipients of grafts with major ABO or bidirectional incompatibility. These findings are limited by our small cord blood recipient population and the presence of some degree of HLA mismatching in nearly all recipients of cord blood transplants evaluated. Further study is required in larger populations of cord blood transplant recipients to better understand the impact of ABO compatibility status on marrow engraftment, together with variables including the cellular composition of the cord blood graft and host immune factors. Table 1 Rate of non-engraftment and days to neutrophil and platelet engraftment following allo-HSCT according to ABO compatibility, including standard deviation and statistical calculation (*indicates statistically significant value). Table 1. Rate of non-engraftment and days to neutrophil and platelet engraftment following allo-HSCT according to ABO compatibility, including standard deviation and statistical calculation (*indicates statistically significant value). Disclosures No relevant conflicts of interest to declare.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2016
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 8
    Online Resource
    Online Resource
    American Society of Hematology ; 2015
    In:  Blood Vol. 126, No. 12 ( 2015-09-17), p. 1516-1516
    In: Blood, American Society of Hematology, Vol. 126, No. 12 ( 2015-09-17), p. 1516-1516
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2015
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 9
    In: Transfusion, Wiley, Vol. 61, No. 2 ( 2021-02), p. 410-422
    Abstract: Transfusion of red blood cells (RBC) is a common procedure, which when prescribed inappropriately can result in adverse patient outcomes. This study sought to determine the impact of a multi‐faceted intervention on unnecessary RBC transfusions at hospitals with a baseline appropriateness below 90%. Study Design and Methods A prospective medical chart audit of RBC transfusions was conducted across 15 hospitals. For each site, 10 RBCs per month transfused to inpatients were audited for a 5‐month pre‐ and 10‐month post‐intervention period, with each transfusion adjudicated for appropriateness based on pre‐set criteria. Hospitals with appropriateness rates below 90% underwent a 3‐month intervention which included: adoption of standardized RBC guidelines, staff education, and prospective transfusion order screening by blood bank technologists. Proportions of RBC transfusions adjudicated as appropriate and the total number of RBC units transfused per month in the pre‐ and post‐intervention period were examined. Results Over the 15‐month audit period, at the 13 hospital sites with a baseline appropriateness below 90%, 1950 patients were audited of which 81.2% were adjudicated as appropriate. Proportions of appropriateness and single‐unit orders increased from 73.5% to 85% and 46.2% to 68.2%, respectively from pre‐ to post‐intervention ( P   〈  .0001). Pre‐ and post‐transfusion hemoglobin levels and the total number of RBCs transfused decreased from baseline ( P  〈 .05). The median pre‐transfusion hemoglobin decreased from a baseline of 72.0 g/L to 69.0 g/L in the post‐intervention period ( P   〈  .0001). RBC transfusions per acute inpatient days decreased significantly in intervention hospitals, but not in control hospitals ( P   〈  .001). The intervention had no impact on patient length of stay, need for intensive care support, or in‐hospital mortality. Conclusion This multifaceted intervention demonstrated a marked improvement in RBC transfusion appropriateness and reduced overall RBC utilization without impacts on patient safety.
    Type of Medium: Online Resource
    ISSN: 0041-1132 , 1537-2995
    URL: Issue
    Language: English
    Publisher: Wiley
    Publication Date: 2021
    detail.hit.zdb_id: 2018415-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 10
    In: Transfusion and Apheresis Science, Elsevier BV, Vol. 56, No. 3 ( 2017-06), p. 322-329
    Type of Medium: Online Resource
    ISSN: 1473-0502
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2017
    detail.hit.zdb_id: 2129669-8
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...